Precision BioSciences
DTIL | NASDAQ
$7.28
-$0.29 (-3.77%)
At close: Nov 16, 2026, 4:00 PM ET
$7.20
-$0.08 (-1.10%)
After-hours:
Nov 16, 2026, 7:30 PM ET
-3.77%
(1D)No price chart data available for 1D timeframe.
Rating
34
Fundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #683/1021 (Top 67%)
Key Statistics
Market Data
Market Cap $203.37M
1D Range
7.25 7.64
52W Range
3.57 10.60
Valuation (TTM)
PE -5.87
PB 3.93
EV/EBITDA -4.25
Valuation (NTM)
Forward PE N/A
Forward PEG 0.11
Price Target $20.00
Cash Flow
FCF Yield -25.5%
SBC Adj. FCF Yield -29.6%
SBC Impact -16.2%
Margins
Gross Margin 98.7%
Operating Margin -34.9%
FCF Margin -115.0%
Growth (CAGR)
Revenue 3Y | 5Y -4.8% |
-17.5%
Dil EPS 3Y | 5Y -26.7% |
66.5%
FCF 3Y | 5Y -3.0% |
4.1%
Returns
ROA -32.0%
ROE -58.1%
ROIC -31.8%
Financial Health
Net Cash
$80.19M
Current Ratio 10.47
Interest Coverage -28.56
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Precision BioSciences, Inc. is a clinical-stage biotechnology firm based in the United States, specializing in the creation of both in vivo gene editing solutions and ex vivo allogeneic CAR T-cell the...
Sector Healthcare
Industry Biotechnology
Employees 67
IPO Date Mar 28, 2019
Website www.precisionbiosciences.com
Fiscal Year January - December
Latest News
No news articles available yet.
Earnings
Latest Earnings
Nov 3, 2026
EPS
-$0.28
Beat +67.06%
YoY:
+84.78% REV
$1.25M
Miss -9.09%
YoY:
+9515.38%Next Earnings
Mar 11, 2027
EPS Est
Pro
Rev Est
Pro
Analyst Summary
# of Analysts
1
Consensus
Buy
Price Target
$20.00
Upside
+174.73%
Buy (1)
Hold (0)
Sell (0)
Add to Watchlist
Select watchlists to add or remove DTIL